Vir Biotechnology to Present New Therapy Data at EASL 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Vir Biotechnology "announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL Congress 2026 in Barcelona, Spain, May 27-30, 2026. Tobevibart and elebsiran are investigational agents being evaluated as a novel combination regimen administered monthly as two separate sequential subcutaneous injections for the treatment of CHD. The combination is designed to disrupt the HDV life cycle at multiple points by addressing both viral entry and the sustained presence of hepatitis B surface antigen (HBsAg) that enables ongoing HDV replication. Tobevibart is an investigational broadly neutralizing monoclonal antibody (mAb) targeting HBsAg. It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart was identified using Vir Biotechnology's proprietary mAb discovery platform. The Fc domain has been engineered to increase immune engagement and clearance of HBsAg immune complexes and incorporates Xencor's Xtend(TM) technology to extend half-life. Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) licensed from Alnylam Pharmaceuticals, Inc. It is designed to degrade hepatitis B virus RNA transcripts and limit the production of HBsAg."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VIR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VIR
Wall Street analysts forecast VIR stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.610
Low
12.00
Averages
15.60
High
24.00
Current: 8.610
Low
12.00
Averages
15.60
High
24.00
About VIR
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Superstring Capital Acquires New Position in Vir Biotechnology
- New Investment Position: Superstring Capital Management disclosed a new position in Vir Biotechnology by acquiring 730,548 shares in Q1 2026, with an estimated transaction value of $5.82 million, indicating confidence in the company's future developments.
- Increased Position Value: By quarter-end, Superstring's position in Vir was valued at $6.55 million, reflecting both trading activity and price appreciation, which underscores investor recognition of the company's potential.
- Strong Financial Position: Vir Biotechnology reported $809.3 million in cash and investments at the start of Q2, while also expecting to receive an additional $315 million from its collaboration with Astellas, enhancing its financial flexibility to support future R&D.
- Significant Clinical Progress: Vir's chronic hepatitis delta program showed encouraging Phase 2 data, with 88% of evaluated patients achieving undetectable virus levels by Week 96, and the company anticipates Phase 3 data from its lead study in Q4 2026, further boosting market confidence.
See More
Superstring Capital Acquires Shares in Vir Biotechnology
- Share Acquisition: Superstring Capital acquired 730,548 shares of Vir Biotechnology in Q1, with an estimated transaction value of $5.82 million, reflecting confidence in the company's future developments.
- AUM Growth: This transaction resulted in a 4.16% increase in Superstring Capital's 13F reportable AUM, indicating that its investment strategy in the biotechnology sector is yielding positive results.
- Strong Financial Position: Vir Biotechnology reported $809.3 million in cash and cash equivalents at the end of Q2, and expects to receive an additional $315 million from its collaboration with Astellas, enhancing its funding for future R&D.
- Clinical Progress: Vir's chronic hepatitis program showed that 88% of patients achieved undetectable virus levels through Week 96 in Phase 2 trials, with pivotal Phase 3 data expected in Q4 2026, potentially leading to significant breakthroughs for the company.
See More
SB Investment Advisers Reduces Stake in Vir Biotechnology
- Share Reduction Details: SB Investment Advisers reported a sale of 2,168,884 shares of Vir Biotechnology in its SEC filing dated May 15, 2026, with an estimated trade value of $17.28 million, indicating a strategic adjustment in its investment approach.
- Market Performance Analysis: As of May 15, 2026, Vir Biotechnology's stock price stood at $8.79, reflecting a 93% increase over the past year, significantly outperforming the S&P 500's approximate 25% gain, showcasing the company's robust market performance.
- Financial Overview: Vir Biotechnology has a market capitalization of $1.48 billion, with a trailing twelve-month revenue of $64.7 million and a net loss of $442.72 million, indicating ongoing challenges in profitability, yet it maintains a strong liquidity position with $809.3 million in cash and investments.
- Strategic Development Dynamics: Despite trimming over 2 million shares, SB Investment Advisers still holds approximately $98 million in Vir, suggesting confidence in the company's long-term potential in oncology and hepatitis, particularly following significant advancements in its partnership with Astellas.
See More
Boxer Capital Increases Stake in Vir Biotechnology
- Share Acquisition: On May 15, 2026, Boxer Capital Management disclosed the purchase of 1,241,000 shares of Vir Biotechnology, valued at approximately $9.89 million, indicating increased confidence in the company's prospects.
- Stake Increase: This transaction raised Boxer Capital's stake in Vir Biotechnology to 2.2%, highlighting its significant interest in the company as reported in the 13F filing.
- Financial Performance: Vir Biotechnology's market value increased by $12.95 million in Q1 2026, despite a net income loss of $442.72 million; however, its stock price surged 100% over the past year, significantly outperforming the S&P 500's 25% increase.
- Future Outlook: Vir Biotechnology reported encouraging Phase 2 data in chronic hepatitis delta, with pivotal Phase 3 trials for its prostate cancer treatment expected in 2027, raising questions about its ability to achieve sustainable commercialization amidst investor scrutiny.
See More
GT Biopharma Initiates Phase 1 Trial of GTB-5550 for Solid Tumors
- Trial Launch: On May 14, 2026, GT Biopharma announced that the first patient has been dosed in the Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in treating historically resistant solid tumors.
- Innovative Dosing Method: GTB-5550 is the first TriKE® molecule tested with subcutaneous dosing, administered for five consecutive days in the abdominal area during each four-week cycle, which is expected to enhance patient compliance and reduce treatment-related side effects.
- Broad Tumor Type Coverage: The trial is designed as a basket study encompassing seven solid tumor types, including prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder cancers, indicating the potential applicability of GTB-5550 across multiple difficult-to-treat tumors.
- Strong Market Demand: With prostate and pancreatic cancers historically unresponsive to standard immunotherapies, GTB-5550 is poised to address this significant unmet medical need, enhancing the company's competitiveness in the rapidly evolving immuno-oncology market.
See More
Vicki Sato Sells 22,000 Shares of Vir Biotechnology Stock
- Transaction Overview: Vicki Sato sold 22,000 shares of common stock for approximately $221,000 according to SEC Form 4, retaining 1,078,391 shares post-sale, valued at around $10.78 million, indicating her continued confidence in the company.
- Trading Plan: The sale was part of a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025, suggesting that Sato is engaging in routine portfolio management rather than reacting to market fluctuations.
- Ownership Proportion: This transaction represented 2% of Sato's direct holdings, leaving her with approximately 77.5% of her initial position, which underscores her long-term commitment and confidence in the company.
- Company Overview: Vir Biotechnology focuses on developing monoclonal antibodies and RNA-based therapeutics for infectious diseases like COVID-19 and HIV; despite a net loss of $125.7 million in Q1, the company holds $809.3 million in cash and investments, ensuring operational sustainability.
See More
Superstring Capital Acquires New Position in Vir Biotechnology
- New Investment Position: Superstring Capital Management disclosed a new position in Vir Biotechnology by acquiring 730,548 shares in Q1 2026, with an estimated transaction value of $5.82 million, indicating confidence in the company's future developments.
- Increased Position Value: By quarter-end, Superstring's position in Vir was valued at $6.55 million, reflecting both trading activity and price appreciation, which underscores investor recognition of the company's potential.
- Strong Financial Position: Vir Biotechnology reported $809.3 million in cash and investments at the start of Q2, while also expecting to receive an additional $315 million from its collaboration with Astellas, enhancing its financial flexibility to support future R&D.
- Significant Clinical Progress: Vir's chronic hepatitis delta program showed encouraging Phase 2 data, with 88% of evaluated patients achieving undetectable virus levels by Week 96, and the company anticipates Phase 3 data from its lead study in Q4 2026, further boosting market confidence.
See More
Superstring Capital Acquires Shares in Vir Biotechnology
- Share Acquisition: Superstring Capital acquired 730,548 shares of Vir Biotechnology in Q1, with an estimated transaction value of $5.82 million, reflecting confidence in the company's future developments.
- AUM Growth: This transaction resulted in a 4.16% increase in Superstring Capital's 13F reportable AUM, indicating that its investment strategy in the biotechnology sector is yielding positive results.
- Strong Financial Position: Vir Biotechnology reported $809.3 million in cash and cash equivalents at the end of Q2, and expects to receive an additional $315 million from its collaboration with Astellas, enhancing its funding for future R&D.
- Clinical Progress: Vir's chronic hepatitis program showed that 88% of patients achieved undetectable virus levels through Week 96 in Phase 2 trials, with pivotal Phase 3 data expected in Q4 2026, potentially leading to significant breakthroughs for the company.
See More
SB Investment Advisers Reduces Stake in Vir Biotechnology
- Share Reduction Details: SB Investment Advisers reported a sale of 2,168,884 shares of Vir Biotechnology in its SEC filing dated May 15, 2026, with an estimated trade value of $17.28 million, indicating a strategic adjustment in its investment approach.
- Market Performance Analysis: As of May 15, 2026, Vir Biotechnology's stock price stood at $8.79, reflecting a 93% increase over the past year, significantly outperforming the S&P 500's approximate 25% gain, showcasing the company's robust market performance.
- Financial Overview: Vir Biotechnology has a market capitalization of $1.48 billion, with a trailing twelve-month revenue of $64.7 million and a net loss of $442.72 million, indicating ongoing challenges in profitability, yet it maintains a strong liquidity position with $809.3 million in cash and investments.
- Strategic Development Dynamics: Despite trimming over 2 million shares, SB Investment Advisers still holds approximately $98 million in Vir, suggesting confidence in the company's long-term potential in oncology and hepatitis, particularly following significant advancements in its partnership with Astellas.
See More
Boxer Capital Increases Stake in Vir Biotechnology
- Share Acquisition: On May 15, 2026, Boxer Capital Management disclosed the purchase of 1,241,000 shares of Vir Biotechnology, valued at approximately $9.89 million, indicating increased confidence in the company's prospects.
- Stake Increase: This transaction raised Boxer Capital's stake in Vir Biotechnology to 2.2%, highlighting its significant interest in the company as reported in the 13F filing.
- Financial Performance: Vir Biotechnology's market value increased by $12.95 million in Q1 2026, despite a net income loss of $442.72 million; however, its stock price surged 100% over the past year, significantly outperforming the S&P 500's 25% increase.
- Future Outlook: Vir Biotechnology reported encouraging Phase 2 data in chronic hepatitis delta, with pivotal Phase 3 trials for its prostate cancer treatment expected in 2027, raising questions about its ability to achieve sustainable commercialization amidst investor scrutiny.
See More
GT Biopharma Initiates Phase 1 Trial of GTB-5550 for Solid Tumors
- Trial Launch: On May 14, 2026, GT Biopharma announced that the first patient has been dosed in the Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in treating historically resistant solid tumors.
- Innovative Dosing Method: GTB-5550 is the first TriKE® molecule tested with subcutaneous dosing, administered for five consecutive days in the abdominal area during each four-week cycle, which is expected to enhance patient compliance and reduce treatment-related side effects.
- Broad Tumor Type Coverage: The trial is designed as a basket study encompassing seven solid tumor types, including prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder cancers, indicating the potential applicability of GTB-5550 across multiple difficult-to-treat tumors.
- Strong Market Demand: With prostate and pancreatic cancers historically unresponsive to standard immunotherapies, GTB-5550 is poised to address this significant unmet medical need, enhancing the company's competitiveness in the rapidly evolving immuno-oncology market.
See More
Vicki Sato Sells 22,000 Shares of Vir Biotechnology Stock
- Transaction Overview: Vicki Sato sold 22,000 shares of common stock for approximately $221,000 according to SEC Form 4, retaining 1,078,391 shares post-sale, valued at around $10.78 million, indicating her continued confidence in the company.
- Trading Plan: The sale was part of a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025, suggesting that Sato is engaging in routine portfolio management rather than reacting to market fluctuations.
- Ownership Proportion: This transaction represented 2% of Sato's direct holdings, leaving her with approximately 77.5% of her initial position, which underscores her long-term commitment and confidence in the company.
- Company Overview: Vir Biotechnology focuses on developing monoclonal antibodies and RNA-based therapeutics for infectious diseases like COVID-19 and HIV; despite a net loss of $125.7 million in Q1, the company holds $809.3 million in cash and investments, ensuring operational sustainability.
See More
